GlassScriptPhysician profile
Mary Jo Lechowicz
NPI 1336256031
$17,718.88
in general payments reported to CMS, 2019-2025
8 companies · $93.21 in 2025
The $93.21 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,000 · 2021: $14.48 · 2022: $1,577 · 2023: $38.46 · 2024: $4,232 · 2025: $93.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,080 · Food and Beverage: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,080.00 |
| Food and Beverage | $283.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $10,802.53 | 2019-2023 | Poteligeo |
| Recordati_rare_diseases_inc. | $4,080.00 | 2024 | Sylvant |
| Secura Bio, INC. | $1,651.87 | 2022-2024 | Copiktra |
| Eusa Pharma (US) LLC | $1,000.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $93.21 | 2025 | Tecvayli, Darzalex |
| Abbvie INC. | $76.79 | 2022 | |
| Bausch Health US, LLC | $14.48 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Jo Lechowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.